<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348516</url>
  </required_header>
  <id_info>
    <org_study_id>KMCP-023-101</org_study_id>
    <nct_id>NCT01348516</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of KM-023 After Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kainos Medicine Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kainos Medicine Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and pharmacokinetics of KM-023 after
      single/multiple dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/ Tolerability Evaluation</measure>
    <time_frame>participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD</time_frame>
    <description>-number of subjects with Adverse events, Physical examinations, Vital signs, electrocardiogram (ECG), Laboratory tests (including hematology, chemistry, coagulation, urinalysis), circulating immune complexes (CIC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation of KM-023, Area under the plasma concentration versus time curve (AUC) of KM-023</measure>
    <time_frame>participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD</time_frame>
    <description>-Serial blood samples and urine collections for pharmacokinetic evaluations will be conducted pre-dose through post dose in order to evaluate AUC of KM-023</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation of KM-023, Peak Plasma Concentration (Cmax) of KM-023</measure>
    <time_frame>participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD</time_frame>
    <description>-Serial blood samples and urine collections for pharmacokinetic evaluations will be conducted pre-dose through post dose in order to evaluate Cmax of KM-023</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>KM-023</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for KM-023</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KM-023</intervention_name>
    <description>-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.</description>
    <arm_group_label>KM-023</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for KM-023</intervention_name>
    <description>-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.</description>
    <arm_group_label>Placebo for KM-023</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study and signs an Institutional Review Board (IRB) - approved
             informed consent prior to performing any of the screening procedures

          -  Male or female between 20 and 45 years of age at the time of screening, inclusive

          -  A subject with body weight ≥ 45 kg and body mass index (BMI) between 18.5 and 25
             (inclusive). - BMI (kg/m2) = weight (kg) / {height (m)}2

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Able to understand and comply with protocol requirements, instructions and
             protocol-stated restrictions.

        Exclusion Criteria:

          1. A subject with a history of allergies to drugs (aspirin, antibiotics, etc.), or
             history of clinically significant allergies

          2. A subject with clinical evidence or history of hepatic (including carrier of hepatitis
             virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic,
             oncologic, psychiatric, or cardiovascular disease

          3. A subject with a history of gastrointestinal disease or surgery (except simple
             appendectomy or repair of hernia), which can influence the absorption of the study
             drug

          4. A female subject who is pregnant, nursing mother, or sexually active females
             (childbearing potential)

          5. Patients who are taking any of the following medications; Bepridil, cisapride,
             midazolam, pimozide, triazolam, Ergot medications (e.g. Wigraine, cafergot, St. John's
             wort), Phenobarbitol

          6. Patients who have previously demonstrated hypersensitivity to Efavirenz or to one of
             the components of Stocrin or Sustiva

          7. A positive Hepatitis B surface antigen or positive Hepatitis C antibody at screening.

          8. A positive test for HIV antibody (as per local practice)

          9. A subject who has taken any prescribed medication or herbal compounds within 14 days
             prior to the study drug administration. In addition, a subject who has taken any
             over-the-counter drug or vitamin supplements within 7 days prior to the study drug
             administration.

         10. A subject who has participated in any other clinical trial either for investigational
             or marketed drugs within 8 weeks before the study drug administration

         11. A subject who has donated or had loss of ≥ 400 mL of blood within 8 weeks prior to
             start of administration of study drug

         12. The value of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is
             greater than 1.25 times the upper limit of the reference range.

         13. A subject who is unable to abstain from drinking alcoholic beverages throughout the
             study period.

         14. A subject with a history of drug abuse, or a positive urine drug screening test

         15. A subject who heavily takes caffeine or caffeine-containing products, or takes
             grapefruit, grapefruit juice, or grapefruit-containing products

         16. A subject who is unable to eat a standardized meal offered by the study center

         17. A subject who will be previously assigned to treatment during this study (except those
             who did not take any study medications)

         18. Systolic blood pressure outside the range of 80 to 140 mm Hg, or diastolic blood
             pressure outside the range of 60 to 85 mm Hg, or heart rate outside the range of 50 to
             100 beats per minute (bpm) for females; outside and the range of 45 to 100 beats per
             minute (bpm) for male subjects. Blood pressure and heart rate should be taken after 10
             minutes of rest.

         19. The investigator judges the subject not eligible for the study after reviewing
             clinical laboratory results or other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trials Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>July 24, 2012</last_update_submitted>
  <last_update_submitted_qc>July 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

